Abstracts Archive - Page 905 of 2607 - ACR Meeting Abstracts

Abstract Number: 1029 • ACR Convergence 2020
Clinical Characteristics of Patients with Axial Spondyloarthritis in China: Results from the ChinaAS Registry
Jinmei Su¹, Runsheng Wang², Ping Zhu³, Yanhong Wang⁴, Shangzhu Zhang¹, Linyi Peng¹, Min Yang⁵, Ling Lei⁶, Li Qin⁷, Mengtao Li⁸ and Xiaofeng Zeng⁸, ¹Peking Union Medical College Hospital, Department of Rheumatology, Beijing, China (People's Republic), ²Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, ³Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (People's Republic), ⁴Department of Epidemiology and Bio-statistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China (People's Republic), ⁵Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China (People's Republic), ⁶Department of Rheumatology and Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (People's Republic), ⁷Department of Rheumatology, The First People's Hospital of Yunnan Province, Kunming, China (People's Republic), ⁸Peking Union Medical College Hospital, Department of Rheumatology, Beijing, Beijing, China (People's Republic)
Background/Purpose: The ChinaAS is a nationwide, multicenter registry of patients with axial spondyloarthritis (SpA) in China to facilitate research in epidemiology, pathogenesis, diagnosis and treatment…
Abstract Number: 1030 • ACR Convergence 2020
Pain Medication Use Among Ankylosing Spondylitis and Psoriatic Arthritis Patients Before and After Initiation of Biologic Therapy
Theresa Hunter¹, Chi Nguyen², Julie Birt³, Joseph Smith², Mingyang Shan³, Hiangkiat Tan², Jeffrey Lisse³ and Keith Isenberg⁴, ¹Eli Lilly and Company, Indianapolis, ²Healthcore, Inc, Wilmington, DE, ³Eli Lilly and Company, Indianapolis, IN, ⁴Anthem, Inc, Indianapolis, IN
Background/Purpose: Pain is a common symptom among ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients and can be debilitating, making pain management an integral part…
Abstract Number: 1031 • ACR Convergence 2020
Real World Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Ixekizumab
Mwangi Murage¹, Nicole Princic², Julie Park², William Malatestinic¹, Baojin Zhu¹, Bilal Atiya¹, Scott Kern¹, Keri Stenger¹, Aubrey Sprabery¹ and Alexis Ogdie³, ¹Eli Lilly and Company, Indianapolis, IN, ²IBM Watson Health, Cambridge, MA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a systemic condition estimated to affect 0.05%-0.25% of the United States (US)1 population. With approval of ixekizumab (a selectively binding…
Abstract Number: 1032 • ACR Convergence 2020
Epidemiology and Geographic Evaluation of ANCA-associated Vasculitis (AAV) at a Rural Academic Health Center Utilizing an Electronic Health Record (EHR)
Eva Rottmann¹, Jason Bankert², Andrea Berger², Lester Kirchner², Joseph Dewalle², Marissa Meissner³, Jason George², Ion Dan Bucaloiu², Jaya Prakash Sugunaraj², Sudheer Penupolu² and David Bulbin¹, ¹Geisinger Health System, Danville, PA, ²Geisinger Medical Center, Danville, PA, ³Geisinger Medical Center, Danville
Background/Purpose: ANCA-associated vasculitis has a reported prevalence ranging from 3.2 to 9.1 cases per 100,000 individuals, but little is known of geographic variations. The aim of…
Abstract Number: 1033 • ACR Convergence 2020
Systemic Treatment in Sarcoidosis. Study of 377 Patients from a Single University Hospital
David Martinez-Lopez¹, Raul Fernandez-Ramon², José Luis Martín-Varillas³, Lara Sanchez-Bilbao², Inigo Gonzalez-Mazon⁴, Jorge Javier Gaitan-Valdizan⁵, Rosalia Demetrio-Pablo², Miguel Ángel González-Gay⁶ and Ricardo Blanco², ¹Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Sierrallana, Torrelavega, Spain, ⁴Hospital Universitario Marques de Valdecilla, Bezana, Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Sarcoidosis is a multisystemic disease characterized by the formation of non-necrotizing granulomas. The most frequently affected organs are the lungs, skin and eyes. Systemic…
Abstract Number: 1034 • ACR Convergence 2020
Trend of Treatment Plans, and Outcomes of Therapy in Cardiac Sarcoidosis via Analysis of Standardized Uptake Values Score and Ejection Fraction Using a Cardiac PET-CT
Rabia Gill¹, Martin Lavellee¹, Michael Petrides¹, Sarah Ford¹, Gurukripa Kowlgi², Huzaefah Syed³ and Adam Sima³, ¹Virginia Commonwealth University, Richmond, VA, ²Mayo Clinic, Rochester, MN, ³VCU Health, Richmond, VA
Background/Purpose: Pharmacological management of cardiac sarcoidosis (CS) includes immunosuppressive therapy for active lesions, guideline-directed medical therapy for heart failure, and antiarrhythmics. Our goal was to observe the various…
Abstract Number: 1035 • ACR Convergence 2020
Study of Ocular Sarcoidosis and Clusters of Clinical Associations in a Series of 383 Patients with Systemic Sarcoidosis from a Single Hospital
Inigo Gonzalez-Mazon¹, Carmen Alvarez-Reguera², Lara Sanchez-Bilbao², David Martinez-Lopez³, Alba Herrero Morant², Jorge Javier Gaitan-Valdizan⁴, Raul Fernandez-Ramon², Rosalia Demetrio-Pablo² and Ricardo Blanco², ¹Hospital Universitario Marques de Valdecilla, Bezana, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Sarcoidosis is an inflammatory disease which can affect multiple organs. The most frequent affected organs are lungs, skin and eyes. Ocular involvement is a…
Abstract Number: 1036 • ACR Convergence 2020
Ocular Involvement and Treatment in Sarcodosis. Study of 41 Patients of a Series of 383 Patients from a Single University Hospital
David Martinez-Lopez¹, Jorge Javier Gaitan-Valdizan², Raul Fernandez-Ramon³, Rosalia Demetrio-Pablo³, Lara Sanchez-Bilbao³, Inigo Gonzalez-Mazon⁴, José Luis Martín-Varillas⁵, Miguel Ángel González-Gay⁶ and Ricardo Blanco³, ¹Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Bezana, Spain, ⁵Hospital Sierrallana, Torrelavega, Spain, ⁶Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Background: The eye is a common and potential severe complication of sarcoidosis. Topical and systemic corticosteroids are the first-line treatment. Conventional and biological immunosuppressants…
Abstract Number: 1037 • ACR Convergence 2020
Relationship Between Air Quality and Sarcoidosis Inflammatory Activity
Aaron Case¹, Dustin Fraidenburg², Israel Rubinstein² and Christian Ascoli², ¹University of Illinois at Chicago, Chicago, IL, ²Division of Pulmonary,Critical Care, Sleep and Allergy; Department of Medicine, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA, Chicago, IL
Background/Purpose: African Americans [AA] and minorities in the lower socioeconomic strata of Chicago are disproportionately affected by pulmonary sarcoidosis, and regularly exposed to poorer air…
Abstract Number: 1038 • ACR Convergence 2020
STAT1 and JAK2 Are the Most Appropriate Targets of JAK-inhibitor Therapy for Sarcoidosis: An In-silico Meta-nalysis
Marcia Friedman¹, Brian Le², Dongseok Choi² and James Rosenbaum², ¹Oregon Health and Science University, Portland, OR, ²Oregon Health & Science University, Portland, OR
Background/Purpose: Our group was the first to contend that STAT1 mediated genes were expressed in sarcoidosis. Since that time, several other groups have found similar…
Abstract Number: 1039 • ACR Convergence 2020
Tofacitinib as a Steroid-sparing Therapy in Pulmonary Sarcoidosis: Two Prospective Cases and Molecular Analysis
Marcia Friedman¹, Stevens Janelle², Julianna Desmarais³, Daniel Seifer³, Brian Le³, Kimberly Ogle³, Christina Harrington³, Peter Jackson⁴, Dongseok Choi³ and James Rosenbaum³, ¹Oregon Health and Science University, Portland, OR, ²Tuality Healthcare, Hillsboro, OR, ³Oregon Health & Science University, Portland, OR, ⁴Johns Hopkins University, Baltimore, MD
Background/Purpose: Patients with pulmonary sarcoidosis often require prolonged corticosteroids to treat their disease. There are currently no FDA approved steroid-sparing therapies for sarcoidosis. We report…
Abstract Number: 1040 • ACR Convergence 2020
Clinical Characteristics of Sarcoidosis in Asian Population: A 14-year Single Center Retrospective Cohort Study from Thailand
Athiwat Tripipitsiriwat¹, Chulaluk Komoltri¹, Ruchira Ruangchira-Urai¹ and Patompong Ungprasert², ¹Mahidol University, Bangkok, Thailand, ²Cleveland Clinic, Cleveland, OH, Cleveland Heights, OH
Background/Purpose: Data on clinical manifestations of Asians with sarcoidosis are still relatively limited and most of the previously published studies are from East Asia. This…
Abstract Number: 1041 • ACR Convergence 2020
Pharmaco-epidemiology of Non-infectious Ocular Inflammatory Disease in a Tertiary Academic Center
Sanjeev Patil¹, Justine Cheng², Lorraine Provencher³ and Scott Vogelgesang⁴, ¹University of Vermont Medical Center, Essex Junction, VT, ²University of Iowa Hospitals and Clinics, Iowa City, IA, ³Cincinnati Eye Institute, Cincinnati, OH, ⁴University of Iowa Hospitals and Clinics, Iowa City, IA
Background/Purpose: Non-Infectious Ocular inflammatory disease (OID) is a group of immune-mediated diseases involving the ocular surface, uveal tract, retina, optic nerve, and peri-orbital tissue. Patients…
Abstract Number: 1042 • ACR Convergence 2020
Building LSU Uveitis Registry ( BLUR ) Study – a Review of an Academic Rheumatology Center’s Experience and Approach to Uveitis
Anusha Vuppala¹, Kinza Muzzafar¹, Swathi Chalasani¹, Sibile Pardue², Samina Hayat³ and Sarwat Umer³, ¹LSUHSC Shreveport, Shreveport, LA, ²LSUHSC Shreveport, Shreveport, ³LSU Shreveport, Shreveport, LA
Background/Purpose: Uveitis is the most common ophthalmological finding seen by Rheumatologists. Ocular inflammation commonly presents as a manifestation of underlying rheumatic disorder. Local and systemic…
Abstract Number: 1043 • ACR Convergence 2020
Ocular Scleral Pathology and Immune-Mediated Inflammatory Diseases. Study of 170 Patients from a Single Universitary Center
Lara Sanchez-Bilbao¹, Inigo Gonzalez-Mazon², José Luis Martín-Varillas³, David Martinez-Lopez⁴, Carmen Alvarez-Reguera¹, Alba Herrero Morant¹, Rosalia Demetrio-Pablo¹, Vanesa Calvo-Río¹, Miguel Ángel González-Gay⁵ and Ricardo Blanco¹, ¹Hospital Universitario Marques de Valdecilla, Santander, Spain, ²Hospital Universitario Marques de Valdecilla, Bezana, Spain, ³Hospital Sierrallana, Torrelavega, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Ocular scleral pathology (OSP) includes episcleritis and scleritis. Episcleritis is generally a benign disease with a self-limited course, while scleritis is a more severe…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].